{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:03:25Z","timestamp":1772111005788,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,1,17]],"date-time":"2008-01-17T00:00:00Z","timestamp":1200528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s12032-008-9044-4","type":"journal-article","created":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T14:43:17Z","timestamp":1200494597000},"page":"350-355","source":"Crossref","is-referenced-by-count":10,"title":["Bisphosphonate treatment and radiotherapy in metastatic breast cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"A. Ugur","family":"Ural","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferit","family":"Avcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Baran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,17]]},"reference":[{"issue":"1","key":"9044_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","volume":"55","author":"A Jemal","year":"2005","unstructured":"Jemal A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"9044_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165\u201376.","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"9044_CR3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10555-006-9035-x","volume":"25","author":"M Cicek","year":"2006","unstructured":"Cicek M, Oursler MJ. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev. 2006;25(4):635\u201344.","journal-title":"Cancer Metastasis Rev."},{"issue":"7","key":"9044_CR4","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","volume":"96","author":"H Hsu","year":"1999","unstructured":"Hsu H, et al. Tumour necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 1999;96(7):3540\u201345.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"9044_CR5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165\u201376.","journal-title":"Cell."},{"issue":"2","key":"9044_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309\u201319.","journal-title":"Cell."},{"issue":"5","key":"9044_CR7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S8756-3282(02)00685-3","volume":"30","author":"TA Guise","year":"2002","unstructured":"Guise TA, et al. Parathyroid hormone-related protein (PTHrP)(1\u2013139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone. 2002;30(5):670\u20136.","journal-title":"Bone."},{"issue":"22","key":"9044_CR8","first-page":"5849","volume":"59","author":"L Pederson","year":"1999","unstructured":"Pederson L, et al. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res. 1999;59(22):5849\u201355.","journal-title":"Cancer Res."},{"issue":"5","key":"9044_CR9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10585-004-1867-6","volume":"21","author":"RR Mercer","year":"2004","unstructured":"Mercer RR, Miyasaka C, Mastro AM. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin Exp Metastasis. 2004;21(5):427\u201335.","journal-title":"Clin Exp Metastasis."},{"issue":"2","key":"9044_CR10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jcb.10746","volume":"91","author":"AM Mastro","year":"2004","unstructured":"Mastro AM, et al. Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation. J Cell Biochem. 2004;91(2):265\u201376.","journal-title":"J Cell Biochem."},{"issue":"4","key":"9044_CR11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0305-7372(03)00013-6","volume":"29","author":"PJ Hoskin","year":"2003","unstructured":"Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev. 2003;29(4):321\u20137.","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"9044_CR12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.breast.2006.11.001","volume":"16","author":"A Luini","year":"2007","unstructured":"Luini A, et al. The evolution of the conservative approach to breast cancer. Breast. 2007;16(2):120\u20139.","journal-title":"Breast."},{"issue":"4","key":"9044_CR13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S8756-3282(02)00847-5","volume":"31","author":"S Vukmirovic-Popovic","year":"2002","unstructured":"Vukmirovic-Popovic S, et al. Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma. Bone. 2002;31(4):529\u201335.","journal-title":"Bone."},{"issue":"6","key":"9044_CR14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/cncr.11646","volume":"98","author":"R Krempien","year":"2003","unstructured":"Krempien R, et al. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer. 2003;98(6):1318\u201324.","journal-title":"Cancer."},{"issue":"8","key":"9044_CR15","first-page":"1358","volume":"45","author":"N Pandit-Taskar","year":"2004","unstructured":"Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45(8):1358\u201365.","journal-title":"J Nucl Med."},{"issue":"4","key":"9044_CR16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0360-3016(00)01524-8","volume":"49","author":"L Li","year":"2001","unstructured":"Li L, Story M, Legerski RJ. Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys. 2001;49(4):1157\u201362.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"9044_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0936-6555(89)80037-8","volume":"1","author":"PJ Hoskin","year":"1989","unstructured":"Hoskin PJ, Ford HT, Harmer CL. Hemibody irradiation (HBI) for metastatic bone pain in two histologically distinct groups of patients. Clin Oncol (R Coll Radiol). 1989;1(2):67\u20139.","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"2","key":"9044_CR18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0167-8140(92)90338-U","volume":"23","author":"PJ Hoskin","year":"1992","unstructured":"Hoskin PJ, et al. A prospective randomised trial of 4\u00a0Gy or 8\u00a0Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992;23(2):74\u20138.","journal-title":"Radiother Oncol."},{"issue":"2","key":"9044_CR19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-8140(89)90053-4","volume":"14","author":"G Arcangeli","year":"1989","unstructured":"Arcangeli G, et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol. 1989;14(2):95\u2013101.","journal-title":"Radiother Oncol."},{"issue":"9213","key":"9044_CR20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(00)02144-9","volume":"355","author":"PJ Hoskin","year":"2000","unstructured":"Hoskin PJ, et al. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000;355(9213):1428\u20139.","journal-title":"Lancet."},{"issue":"2","key":"9044_CR21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.bjc.6602694","volume":"93","author":"AU Ural","year":"2005","unstructured":"Ural AU, Avcu F. Evolving therapeutic role of bisphosphonates in multiple myeloma. Br J Cancer. 2005;93(2):267\u20138.","journal-title":"Br J Cancer."},{"issue":"6","key":"9044_CR22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","volume":"88","author":"M Sato","year":"1991","unstructured":"Sato M, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88(6):2095\u2013105.","journal-title":"J Clin Invest."},{"issue":"3","key":"9044_CR23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbrc.2004.11.075","volume":"328","author":"JF Bukowski","year":"2005","unstructured":"Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun. 2005;328(3):746\u201350.","journal-title":"Biochem Biophys Res Commun."},{"issue":"6 Suppl 21","key":"9044_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.37421","volume":"29","author":"JR Green","year":"2002","unstructured":"Green JR. Preclinical pharmacology of zoledronic acid. Semin Oncol. 2002;29(6 Suppl 21):3\u201311.","journal-title":"Semin Oncol."},{"issue":"2","key":"9044_CR25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbrc.2005.07.120","volume":"336","author":"AU Ural","year":"2005","unstructured":"Ural AU, Avcu F. Bisphosphonates may potentiate radiation effects: a new approach in cancer treatment? Biochem Biophys Res Commun. 2005;336(2):373\u20134.","journal-title":"Biochem Biophys Res Commun."},{"issue":"18","key":"9044_CR26","doi-asserted-by":"crossref","first-page":"15309","DOI":"10.1074\/jbc.M201253200","volume":"277","author":"X Li","year":"2002","unstructured":"Li X, et al. Inhibition of protein geranylgeranylation and RhoA\/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem. 2002;277(18):15309\u201316.","journal-title":"J Biol Chem."},{"issue":"7","key":"9044_CR27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1634\/theoncologist.11-7-841","volume":"11","author":"G Carteni","year":"2006","unstructured":"Carteni G, et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist. 2006;11(7):841\u20138.","journal-title":"Oncologist."},{"issue":"12","key":"9044_CR28","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1008238422151","volume":"8","author":"JJ Vinholes","year":"1997","unstructured":"Vinholes JJ, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 1997;8(12):1243\u201350.","journal-title":"Ann Oncol."},{"issue":"5","key":"9044_CR29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF02983818","volume":"78","author":"AU Ural","year":"2003","unstructured":"Ural AU, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol. 2003;78(5):443\u20139.","journal-title":"Int J Hematol."},{"issue":"2","key":"9044_CR30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-2141.1998.00976.x","volume":"103","author":"MV Dhodapkar","year":"1998","unstructured":"Dhodapkar MV, et al. Anti-myeloma activity of pamidronate in vivo. Br J Haematol. 1998;103(2):530\u20132.","journal-title":"Br J Haematol."},{"issue":"2","key":"9044_CR31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384","volume":"96","author":"V Kunzmann","year":"2000","unstructured":"Kunzmann V, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96(2):384\u201392.","journal-title":"Blood."},{"issue":"6","key":"9044_CR32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199808063390609","volume":"339","author":"GR Mundy","year":"1998","unstructured":"Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 1998;339(6):398\u2013400.","journal-title":"N Engl J Med."},{"issue":"6","key":"9044_CR33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0609.2005.00427.x","volume":"74","author":"F Avcu","year":"2005","unstructured":"Avcu F, et al. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB\/c mice by intraperitoneal injection of pristane. Eur J Haematol. 2005;74(6):496\u2013500.","journal-title":"Eur J Haematol."},{"issue":"2","key":"9044_CR34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T","volume":"83","author":"S Magnetto","year":"1999","unstructured":"Magnetto S, et al. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999;83(2):263\u20139.","journal-title":"Int J Cancer."},{"issue":"3","key":"9044_CR35","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"G Pluijm van der","year":"1996","unstructured":"van der Pluijm G, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996;98(3):698\u2013705.","journal-title":"J Clin Invest."},{"issue":"4","key":"9044_CR36","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1543","volume":"8","author":"AU Ural","year":"2006","unstructured":"Ural AU, et al. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res. 2006;8(4):R52.","journal-title":"Breast Cancer Res."},{"issue":"8","key":"9044_CR37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.cad.0000175582.01446.6f","volume":"16","author":"JK Woodward","year":"2005","unstructured":"Woodward JK, et al. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs. 2005;16(8):845\u201354.","journal-title":"Anticancer Drugs."},{"issue":"8","key":"9044_CR38","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001;84(8):1126\u201334.","journal-title":"Br J Cancer."},{"issue":"4","key":"9044_CR39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/02841860500492083","volume":"45","author":"AU Ural","year":"2006","unstructured":"Ural AU, Avcu F. Additive\/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms? Acta Oncol. 2006;45(4):491\u20132.","journal-title":"Acta Oncol."},{"issue":"2","key":"9044_CR40","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijrobp.2004.09.065","volume":"61","author":"E Algur","year":"2005","unstructured":"Algur E, Macklis RM, Hafeli UO. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys. 2005;61(2):535\u201342.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"9044_CR41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2005.06.003","volume":"50","author":"AU Ural","year":"2005","unstructured":"Ural AU, Avcu F. Radiosensitizing effect of zoledronic acid in small cell lung cancer. Lung Cancer 2005;50(2):271\u20132.","journal-title":"Lung Cancer"},{"issue":"9","key":"9044_CR42","first-page":"2580","volume":"5","author":"B Kurdoglu","year":"1999","unstructured":"Kurdoglu B, et al. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines. Clin Cancer Res. 1999;5(9):2580\u20137.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"9044_CR43","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/gcc.10296","volume":"38","author":"WG McKenna","year":"2003","unstructured":"McKenna WG, Muschel RJ. Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer. 2003;38(4):330\u20138.","journal-title":"Genes Chromosomes Cancer."},{"issue":"8","key":"9044_CR44","first-page":"1727","volume":"56","author":"EJ Bernhard","year":"1996","unstructured":"Bernhard EJ, et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 1996;56(8):1727\u201330.","journal-title":"Cancer Res."},{"issue":"2","key":"9044_CR45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10585-006-9025-y","volume":"23","author":"F Journe","year":"2006","unstructured":"Journe F, et al. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clin Exp Metastasis. 2006;23(2):135\u201347.","journal-title":"Clin Exp Metastasis."},{"issue":"21","key":"9044_CR46","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003.","unstructured":"Hillner BE, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003.;21(21):4042\u201357.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9044_CR47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0360-3016(03)00525-X","volume":"57","author":"V Kouloulias","year":"2003","unstructured":"Kouloulias V, et al. Radiotherapy in conjunction with intravenous infusion of 180\u00a0mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys. 2003;57(1):143\u201357.","journal-title":"Int J Radiat Oncol Biol Phys."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9044-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-008-9044-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9044-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T21:35:55Z","timestamp":1588282555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-008-9044-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,17]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["9044"],"URL":"https:\/\/doi.org\/10.1007\/s12032-008-9044-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,17]]}}}